- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Stopping TKIs Proven Safe in Chronic Phase CML
June 11th 2016, 3:24am
European Hematology Association Congress
Tyrosine kinase inhibitors can safely be halted in select patients with chronic phase chronic myeloid leukemia followed a maintained deep molecular remission.
Blinatumomab Nearly Doubles Survival in Acute Lymphoblastic Leukemia
June 11th 2016, 2:55am
European Hematology Association Congress
The median overall survival with the anti-CD19 immunotherapy blinatumomab was 7.7 months versus 4 months with standard chemotherapy in patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to results from the phase III TOWER study.
Ibrutinib Highly Effective for Del17p CLL in Combined Analysis
June 11th 2016, 2:32am
European Hematology Association Congress
Ibrutinib continued to demonstrate impressive antitumor activity in a pooled analysis of 243 patients with deletion 17p chronic lymphocytic leukemia.
Dr. Ruben Mesa on COMFORT-I for Myelofibrosis
June 10th 2016, 11:46pm
Cabozantinib Improves Survival in Renal Cell Carcinoma
June 9th 2016, 1:01am
Cabozantinib reduced the risk of death by 34% compared with everolimus in patients with previously treated advanced renal cell carcinoma, according to updated data from the phase III METEOR trial.
Dr. Edward Kim on ASCO's TAPUR Trial
June 9th 2016, 12:33am
Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the significance of the TAPUR clinical trial, which is being conducted by ASCO.
CAR Therapy Achieves Durable Responses in Refractory Lymphoma
June 8th 2016, 4:16am
Three-fourths of patients with advanced lymphoma achieved durable objective responses to treatment with chimeric antigen receptor T-cell therapy targeting CD19 even after a low-dose chemotherapy conditioning regimen.
Pembrolizumab/Bevacizumab Combo Passes Safety Test in Recurrent Glioblastoma
June 8th 2016, 3:38am
An immunotherapy/antiangiogenesis combination proved to be safe and tolerable for patients with recurrent glioblastoma, preliminary data from an ongoing trial showed.
Avelumab Highly Effective in Metastatic Merkel Cell Carcinoma
June 8th 2016, 2:14am
The PD-L1 inhibitor avelumab demonstrated durable responses and promising early survival data for patients with pretreated metastatic Merkel cell carcinoma.
High Response Rates Achieved with Pembrolizumab in Refractory Hodgkin Lymphoma
June 7th 2016, 10:06pm
Pembrolizumab (Keytruda) is associated with an exceptional overall response rate in patients with relapsed/refractory Hodgkin lymphoma.
Dr. Ferris on Significance of CheckMate-141 Trial for Head and Neck Cancer
June 7th 2016, 9:59pm
Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).
Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer
June 7th 2016, 9:39pm
Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.
Impressive Upfront Palbociclib PFS Benefit Confirmed in ER+/HER2- Breast Cancer
June 7th 2016, 8:26pm
Adding the CDK 4/6 inhibitor palbociclib (Ibrance) to letrozole reduced the risk of disease progression by 42% compared with letrozole alone in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.
Long-Term Data Deepen Dabrafenib/Trametinib Benefit in Melanoma
June 7th 2016, 8:41am
The combination of dabrafenib and trametinib continued to demonstrate impressive overall survival and progression-free survival findings for patients with BRAF-mutant metastatic melanoma in 3-year follow-up data from the phase III COMBI-d study.
Dr. Dummer on NEMO Trial for NRAS-Mutant Melanoma
June 7th 2016, 4:01am
Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses the results of the phase III NEMO trial, which compared the efficacy of binimetinib with dacarbazine in patients with NRAS-mutant metastatic melanoma.
Alectinib Could Represent First-Line Standard in ALK-Positive NSCLC
June 7th 2016, 3:47am
Alectinib improved progression-free survival by 66% compared with the current standard crizotinib as initial inhibitor therapy in patients with advanced or recurrent ALK-positive non–small cell lung cancer.
Long-Term Follow-up Sustains Frontline Nivolumab/Ipilimumab Benefit in Melanoma
June 7th 2016, 3:22am
At a minimum follow-up of 18 months, the combination of nivolumab and ipilimumab reduced the risk of disease progression by 58% compared with ipilimumab alone, and single-agent nivolumab lowered the risk of progression by 45% versus ipilimumab monotherapy in patients with advanced melanoma.
Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma
June 7th 2016, 3:20am
David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).
Binimetinib Shows Rare PFS Benefit in NRAS-Mutant Melanoma
June 7th 2016, 2:44am
The MEK inhibitor binimetinib reduced the risk of progression or death by 38% compared with dacarbazine in patients with NRAS-mutant metastatic melanoma.